Research Library

Retatrutide Identity and Quality: Connecting the Material to the Evidence

Retatrutide’s clinical research is tied to a precisely defined molecule. Connecting any tested material to that evidence requires more than matching the name—it requires credible identity, content,...

MRI-Measured Liver Fat in the LY3437943 Phase 2 Substudy

Investigators reported striking liver-fat changes in a randomized LY3437943 substudy—one of the most closely watched findings outside the primary body-weight and glycemic endpoints. The study offer...

Understanding Retatrutide, Tirzepatide, and Semaglutide Trial Comparisons

Retatrutide, tirzepatide, and semaglutide represent three stages in the development of incretin-based metabolic research: single-, dual-, and triple-receptor strategies. Comparing them is scientifi...

Retatrutide Safety: What the Evidence Currently Shows

Retatrutide’s clinical program has already produced a recognizable tolerability profile. Understanding what researchers observed—and what longer follow-up still needs to establish—is essential to e...

Retatrutide Phase 3: What the TRIUMPH Program Has Actually Shown

TRIUMPH is an unusually broad Phase 3 program spanning general obesity, type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, head-to-head comparison, treatment escalation, longer-t...

What Is Retatrutide? Why the Triple-Agonist Design Matters

Lilly’s LY3437943 represents one of the most ambitious ideas in modern metabolic-peptide research: combining GIP, GLP-1, and glucagon-receptor activity within one investigated molecule. The program...

What the LY3437943 DXA Substudy Reported About Body Composition

The LY3437943 body-composition substudy drew interest because large body-weight changes were accompanied by substantial changes in measured fat mass. The next research question is how lean tissue, ...

Body-Weight Findings in Retatrutide Trials

Trials of Lilly’s investigated LY3437943 have reported some of the largest mean body-weight changes in randomized metabolic research. These results are a major reason for scientific interest in the...

Retatrutide Full Evidence Review

Retatrutide has a well-defined molecular and receptor-pharmacology record, substantial randomized evidence for weight and glycemic endpoints, and a large ongoing clinical program. Evidence strength...

Retatrutide: Complete Research Overview

LY3437943, the investigational molecule developed by Eli Lilly and commonly known as retatrutide, has become one of the most closely watched subjects in current metabolic research. It was designed ...